<p>LeMaitre Vascular, Inc.（纳斯达克代码：LMAT - 获取免费报告）的股票目前被八位分析师给予了 “适度买入” 的平均推荐，Marketbeat Ratings 报告称。三位投资分析师对该股票给予了持有推荐，四位给予了买入推荐，还有一位给予了强烈买入推荐。在过去一年中，更新了对该股票覆盖的经纪人中，平均一年目标价为 100.20 美元。</p>
<p>获取 <strong>LeMaitre Vascular</strong> 警报：</p>
<p>几位股票研究分析师对该股票进行了评论。Zacks Research 在 11 月 7 日的报告中将 LeMaitre Vascular 的股票评级从 “持有” 上调至 “强烈买入”。Roth Capital 在 11 月 5 日的报告中重申了 “买入” 评级，并对 LeMaitre Vascular 的股票设定了 108.00 美元的目标价。富国银行在 11 月 7 日的研究报告中将 LeMaitre Vascular 的目标价从 97.00 美元下调至 93.00 美元，并对该股票设定了 “等权重” 评级。Weiss Ratings 在周一的研究报告中将 LeMaitre Vascular 的评级从 “持有（c+）” 上调至 “买入（b-）”。最后，华尔街禅在 12 月 6 日的报告中将 LeMaitre Vascular 的评级从 “买入” 下调至 “持有”。</p>
<p><strong>查看我们最新的 LMAT 股票报告</strong></p>
<h2>LeMaitre Vascular 价格表现</h2>
<p>纳斯达克 LMAT 的股票在周五开盘价为 85.27 美元。LeMaitre Vascular 的 52 周低点为 71.42 美元，52 周高点为 105.55 美元。该公司的 50 日移动平均价格为 86.26 美元，200 日移动平均价格为 87.18 美元。公司的速动比率为 11.45，流动比率为 13.58，债务与股本比率为 0.44。该公司的市值为 19.3 亿美元，市盈率为 36.75，市盈率/增长比率为 2.10，贝塔值为 0.68。</p>
<p>LeMaitre Vascular（纳斯达克代码：LMAT - 获取免费报告）最近于 11 月 6 日公布了季度财报。这家医疗器械供应商报告本季度每股收益为 0.62 美元，超出市场共识预期的 0.57 美元，超出 0.05 美元。该公司本季度的收入为 6105 万美元，而分析师预期为 6218 万美元。LeMaitre Vascular 的净利润率为 22.14%，股本回报率为 14.06%。与去年同期相比，该公司的季度收入增长了 11.4%。在去年同期，该公司每股收益为 0.49 美元。LeMaitre Vascular 将其 2025 财年的指导目标设定为每股收益 2.480-2.530 美元，2025 年第四季度的指导目标为每股收益 0.640-0.690 美元。平均而言，卖方分析师预计 LeMaitre Vascular 本年度每股收益为 1.94 美元。</p>
<h2>LeMaitre Vascular 股息公告</h2>
<p>该公司最近宣布了一项季度股息，该股息于 12 月 4 日支付。11 月 20 日的登记投资者获得了每股 0.20 美元的股息。该股息的除息日期为 11 月 20 日。这相当于每年 0.80 美元的股息，收益率为 0.9%。LeMaitre Vascular 的股息支付比率为 34.48%。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者和对冲基金最近增加或减少了对 LMAT 的持股。Tudor Investment Corp ET AL 在第三季度购买了 LeMaitre Vascular 的新股份，价值约 605.6 万美元。CIBC Bancorp USA Inc. 在第三季度获得了 LeMaitre Vascular 的新头寸，价值约 79.9 万美元。Advisory Services Network LLC 在第三季度获得了 LeMaitre Vascular 的新头寸，价值约 9.8 万美元。PharVision Advisers LLC 在第三季度购买了 LeMaitre Vascular 的新头寸，价值约 35.5 万美元。最后，Verition Fund Management LLC 在第三季度将其在 LeMaitre Vascular 的持股增加了 136.2%。Verition Fund Management LLC 现在拥有该医疗器械供应商的 16,907 股股票，价值 148 万美元，在此期间又购买了 9,750 股。对冲基金和其他机构投资者持有该公司 84.64% 的股票。</p>
<h2>关于 LeMaitre Vascular</h2>
<p>（获取免费报告）</p>
<p>LeMaitre Vascular, Inc. 在全球范围内开发、制造和销售用于血管外科领域的医疗设备和植入物。它提供人类尸体组织冷冻保存服务；用于查看血管腔的光纤导管——血管镜；用于从动脉中去除血栓的取栓导管；用于去除静脉系统中血栓的取栓导管；暂时阻断血流的阻塞导管；以及用于将血液和其他液体灌注到血管中的灌注导管。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 LeMaitre Vascular</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>股票拆分意味着什么？</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>股票市场行业：它们是什么，有多少个？</li>
<li>MongoDB 可能会创下新高——但你需要迅速行动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 LeMaitre Vascular 吗？</h2>
<p>在考虑 LeMaitre Vascular 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 LeMaitre Vascular 并不在名单上。</p>
<p>虽然勒梅特微管医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

勒梅特微管医疗

<p>LeMaitre Vascular, Inc.（纳斯达克代码：LMAT）获得了八位分析师的共识 “适度买入” 评级。该股票的 1 年价格目标为 100.20 美元。最近的分析师行动包括评级的上调和下调，评级中包含持有、买入和强力买入的混合。该公司报告的季度收益超出预期，并已设定未来的每股收益指引。机构投资者在调整其在公司的持股方面表现活跃。LeMaitre Vascular 开发和销售用于血管手术的医疗设备</p>

<p>Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been assigned an average recommendation of &#34;Moderate Buy&#34; from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $100.20.</p>
<div class="lb-trans"><p>LeMaitre Vascular, Inc.（纳斯达克代码：LMAT - 获取免费报告）的股票目前被八位分析师给予了 “适度买入” 的平均推荐，Marketbeat Ratings 报告称。三位投资分析师对该股票给予了持有推荐，四位给予了买入推荐，还有一位给予了强烈买入推荐。在过去一年中，更新了对该股票覆盖的经纪人中，平均一年目标价为 100.20 美元。</p>
</div><p>Get <strong>LeMaitre Vascular</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>LeMaitre Vascular</strong> 警报：</p>
</div><p>Several equities research analysts have commented on the stock. Zacks Research raised shares of LeMaitre Vascular from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Friday, November 7th. Roth Capital reissued a &#34;buy&#34; rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Wells Fargo &amp; Company lowered their target price on LeMaitre Vascular from $97.00 to $93.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Friday, November 7th. Weiss Ratings upgraded LeMaitre Vascular from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research report on Monday. Finally, Wall Street Zen downgraded LeMaitre Vascular from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th.</p>
<div class="lb-trans"><p>几位股票研究分析师对该股票进行了评论。Zacks Research 在 11 月 7 日的报告中将 LeMaitre Vascular 的股票评级从 “持有” 上调至 “强烈买入”。Roth Capital 在 11 月 5 日的报告中重申了 “买入” 评级，并对 LeMaitre Vascular 的股票设定了 108.00 美元的目标价。富国银行在 11 月 7 日的研究报告中将 LeMaitre Vascular 的目标价从 97.00 美元下调至 93.00 美元，并对该股票设定了 “等权重” 评级。Weiss Ratings 在周一的研究报告中将 LeMaitre Vascular 的评级从 “持有（c+）” 上调至 “买入（b-）”。最后，华尔街禅在 12 月 6 日的报告中将 LeMaitre Vascular 的评级从 “买入” 下调至 “持有”。</p>
</div><p><strong>Check Out Our Latest Stock Report on LMAT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 LMAT 股票报告</strong></p>
</div><h2>LeMaitre Vascular Price Performance</h2>
<div class="lb-trans"><h2>LeMaitre Vascular 价格表现</h2>
</div><p>Shares of NASDAQ LMAT opened at $85.27 on Friday. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The business's 50 day moving average price is $86.26 and its 200 day moving average price is $87.18. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The firm has a market cap of $1.93 billion, a P/E ratio of 36.75, a P/E/G ratio of 2.10 and a beta of 0.68.</p>
<div class="lb-trans"><p>纳斯达克 LMAT 的股票在周五开盘价为 85.27 美元。LeMaitre Vascular 的 52 周低点为 71.42 美元，52 周高点为 105.55 美元。该公司的 50 日移动平均价格为 86.26 美元，200 日移动平均价格为 87.18 美元。公司的速动比率为 11.45，流动比率为 13.58，债务与股本比率为 0.44。该公司的市值为 19.3 亿美元，市盈率为 36.75，市盈率/增长比率为 2.10，贝塔值为 0.68。</p>
</div><p>LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The business had revenue of $61.05 million during the quarter, compared to analysts' expectations of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business's quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS. On average, sell-side analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.</p>
<div class="lb-trans"><p>LeMaitre Vascular（纳斯达克代码：LMAT - 获取免费报告）最近于 11 月 6 日公布了季度财报。这家医疗器械供应商报告本季度每股收益为 0.62 美元，超出市场共识预期的 0.57 美元，超出 0.05 美元。该公司本季度的收入为 6105 万美元，而分析师预期为 6218 万美元。LeMaitre Vascular 的净利润率为 22.14%，股本回报率为 14.06%。与去年同期相比，该公司的季度收入增长了 11.4%。在去年同期，该公司每股收益为 0.49 美元。LeMaitre Vascular 将其 2025 财年的指导目标设定为每股收益 2.480-2.530 美元，2025 年第四季度的指导目标为每股收益 0.640-0.690 美元。平均而言，卖方分析师预计 LeMaitre Vascular 本年度每股收益为 1.94 美元。</p>
</div><h2>LeMaitre Vascular Dividend Announcement</h2>
<div class="lb-trans"><h2>LeMaitre Vascular 股息公告</h2>
</div><p>The company also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Investors of record on Thursday, November 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular's dividend payout ratio is 34.48%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，该股息于 12 月 4 日支付。11 月 20 日的登记投资者获得了每股 0.20 美元的股息。该股息的除息日期为 11 月 20 日。这相当于每年 0.80 美元的股息，收益率为 0.9%。LeMaitre Vascular 的股息支付比率为 34.48%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Tudor Investment Corp ET AL purchased a new stake in shares of LeMaitre Vascular during the 3rd quarter worth about $6,056,000. CIBC Bancorp USA Inc. acquired a new position in LeMaitre Vascular in the 3rd quarter worth about $799,000. Advisory Services Network LLC acquired a new position in LeMaitre Vascular in the 3rd quarter worth about $98,000. PharVision Advisers LLC purchased a new position in LeMaitre Vascular during the third quarter worth approximately $355,000. Finally, Verition Fund Management LLC grew its holdings in LeMaitre Vascular by 136.2% in the third quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier's stock valued at $1,480,000 after purchasing an additional 9,750 shares during the period. Hedge funds and other institutional investors own 84.64% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了对 LMAT 的持股。Tudor Investment Corp ET AL 在第三季度购买了 LeMaitre Vascular 的新股份，价值约 605.6 万美元。CIBC Bancorp USA Inc. 在第三季度获得了 LeMaitre Vascular 的新头寸，价值约 79.9 万美元。Advisory Services Network LLC 在第三季度获得了 LeMaitre Vascular 的新头寸，价值约 9.8 万美元。PharVision Advisers LLC 在第三季度购买了 LeMaitre Vascular 的新头寸，价值约 35.5 万美元。最后，Verition Fund Management LLC 在第三季度将其在 LeMaitre Vascular 的持股增加了 136.2%。Verition Fund Management LLC 现在拥有该医疗器械供应商的 16,907 股股票，价值 148 万美元，在此期间又购买了 9,750 股。对冲基金和其他机构投资者持有该公司 84.64% 的股票。</p>
</div><h2>About LeMaitre Vascular</h2>
<div class="lb-trans"><h2>关于 LeMaitre Vascular</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.</p>
<div class="lb-trans"><p>LeMaitre Vascular, Inc. 在全球范围内开发、制造和销售用于血管外科领域的医疗设备和植入物。它提供人类尸体组织冷冻保存服务；用于查看血管腔的光纤导管——血管镜；用于从动脉中去除血栓的取栓导管；用于去除静脉系统中血栓的取栓导管；暂时阻断血流的阻塞导管；以及用于将血液和其他液体灌注到血管中的灌注导管。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than LeMaitre Vascular</li>
<li>How to buy stock: A step-by-step guide for beginners</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>What Does a Stock Split Mean?</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>Stock Market Sectors: What Are They and How Many Are There?</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 LeMaitre Vascular</li>
<li>如何购买股票：初学者的逐步指南</li>
<li>博通股票暴跌 20%——但华尔街认为它将飙升至 500 美元</li>
<li>股票拆分意味着什么？</li>
<li>忘掉芯片：AI 反弹的四个工业投资机会</li>
<li>股票市场行业：它们是什么，有多少个？</li>
<li>MongoDB 可能会创下新高——但你需要迅速行动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=LMAT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in LeMaitre Vascular Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 LeMaitre Vascular 吗？</h2>
</div><p>Before you consider LeMaitre Vascular, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LeMaitre Vascular 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 LeMaitre Vascular 并不在名单上。</p>
</div><p>While LeMaitre Vascular currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然勒梅特微管医疗目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

勒梅特微管医疗公司（NASDAQ:LMAT）被券商一致评级为 “适度买入”